UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

_____________________________________________________________________

Date of Report (Date of earliest event reported): ~~August 29~~October 22, 2025

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

1-11083

04-2695240

~~04-2695240~~

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234

(Address of ~~principal~~Principal ~~executive~~Executive ~~offices~~Offices) (Zip Code)

(508) 683-4000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.01 par value per share

BSX

New York Stock Exchange

0.625% Senior Notes due 2027

BSX27

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item~~ITEM 52.02 ~~Departure~~. RESULTS ofOF ~~Directors~~OPERATIONS orAND ~~Certain~~FINANCIAL ~~Officers; Election of Directors; Appointment of Certain Officers;~~ CONDITION.

~~Compensatory~~On ~~Arrangements~~October 22, 2025, Boston Scientific Corporation issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of ~~Certain~~the ~~Officers~~release is furnished with this report as Exhibit 99.1.

OnThe ~~August~~information ~~29,~~contained ~~2025,~~in ~~Jeffrey~~Item B2.02 ~~Mirviss~~of ~~informed~~this ~~Boston~~Current ~~Scientific~~Report ~~Corporation~~on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “~~Company~~Exchange Act”) ~~that~~or heotherwise ~~has~~subject ~~decided~~ to ~~retire~~the ~~from~~liabilities ~~his~~of ~~role~~that assection, ~~Executive~~nor ~~Vice~~shall ~~President~~it ~~and~~be ~~President,~~deemed ~~Peripheral~~incorporated ~~Interventions~~by ~~effective~~reference asin any filing under the Securities Act of ~~December~~1933 1or the Exchange Act, ~~2025.~~regardless of any general incorporation language in such filing.

~~Mr.~~ITEM ~~Mirviss is expected to remain with the Company as a senior advisor from such time through February 27, 2026 (such date, or any earlier date, the “Retirement Date”)~~9. ~~As a senior advisor, Mr~~01. FINANCIAL ~~Mirviss~~STATEMENTS ~~will~~AND ~~receive a base salary at his current annual base salary of $705,000, prorated through the Retirement Date~~EXHIBITS.

The Company expects to enter into a Retirement Agreement with Mr. Mirviss effective as of the Retirement Date, pursuant to which Mr. Mirviss will be entitled to payments and benefits that are materially consistent with those Mr. Mirviss is entitled to under, and subject to the terms and conditions of, the Company’s Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and equity awards granted thereunder, respectively, each as previously filed with the U.S. Securities and Exchange Commission.(d) Exhibits

Exhibit No. Description

99.1 Press Release issued by Boston Scientific Corporation dated October 22, 2025

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL

document

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	~~September~~October 422, 2025	BOSTON SCIENTIFIC CORPORATION
		By:	/s/ Susan Thompson
			Susan Thompson
			Vice President, Chief Corporate Counsel and Assistant Secretary

Filing Compare · BOSTON SCIENTIFIC CORP